Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,973
archived clinical trials in
High Cholesterol

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
United Osteoporosis Center
mi
from
Gainesville, GA
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
United Osteoporosis Center
mi
from
Gainesville, GA
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
East West Medical Institute
mi
from
Honolulu, HI
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
East West Medical Institute
mi
from
Honolulu, HI
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Solaris Clinical Research
mi
from
Meridian, ID
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Solaris Clinical Research
mi
from
Meridian, ID
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Northwest Heart Clinical Research
mi
from
Arlington Heights, IL
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Northwest Heart Clinical Research
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Cedar-Crosse Research Center
mi
from
Chicago, IL
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Cedar-Crosse Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Midwest CRC
mi
from
Crystal Lake, IL
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Midwest CRC
mi
from
Crystal Lake, IL
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Indiana Heart Physicians
mi
from
Indianapolis, IN
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Indiana Heart Physicians
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Midwest Institute for Clinical Research
mi
from
Indianapolis, IN
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Midwest Institute for Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Hutchinson Clinic
mi
from
Hutchinson, KA
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Hutchinson Clinic
mi
from
Hutchinson, KA
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Community Medical Associates Inc
mi
from
Louisville, KY
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Community Medical Associates Inc
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Maryland Cardiovascular Specialists
mi
from
Baltimore, MD
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Maryland Cardiovascular Specialists
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Overlea Personal Physicians
mi
from
Baltimore, MD
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Overlea Personal Physicians
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Cape Cod Research Institute
mi
from
Hyannis, MA
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Cape Cod Research Institute
mi
from
Hyannis, MA
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
ActivMed Practices & Research
mi
from
Methuen, MA
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
ActivMed Practices & Research
mi
from
Methuen, MA
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Medex Healthcare Research, Inc.
mi
from
Saint Louis, MO
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Medex Healthcare Research, Inc.
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Palm Research Center
mi
from
Las Vegas, NV
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Palm Research Center
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Heart and Vascular Center of New Brunswick LLC
mi
from
Somerset, NJ
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Heart and Vascular Center of New Brunswick LLC
mi
from
Somerset, NJ
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Medex Healthcare Research, Inc.
mi
from
New York, NY
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Medex Healthcare Research, Inc.
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Saratoga Clinical Research LLC
mi
from
Saratoga Springs, NY
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Saratoga Clinical Research LLC
mi
from
Saratoga Springs, NY
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Buffalo Cardiology & Pulmonary Associates
mi
from
Williamsville, NY
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Buffalo Cardiology & Pulmonary Associates
mi
from
Williamsville, NY
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Asheville Cardiology Associates
mi
from
Asheville, NC
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Asheville Cardiology Associates
mi
from
Asheville, NC
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Metrolina Internal Medicine
mi
from
Charlotte, NC
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Metrolina Internal Medicine
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
High Point Clinical Trials Center
mi
from
High Point, NC
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
High Point Clinical Trials Center
mi
from
High Point, NC
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Boice-Willis Clinic
mi
from
Rocky Mount, NC
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Boice-Willis Clinic
mi
from
Rocky Mount, NC
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
PMG Research of Wilmington
mi
from
Wilmington, NC
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
PMG Research of Wilmington
mi
from
Wilmington, NC
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Lillestol Research LLC
mi
from
Fargo, ND
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Lillestol Research LLC
mi
from
Fargo, ND
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Aventiv Research
mi
from
Columbus, OH
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Aventiv Research
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
South Oklahoma Heart Research
mi
from
Oklahoma City, OK
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
South Oklahoma Heart Research
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Portland Preventive Cardiology, LLC
mi
from
Portland, OR
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Portland Preventive Cardiology, LLC
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Partners in Clinical Research, LLC
mi
from
Cumberland, RI
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Partners in Clinical Research, LLC
mi
from
Cumberland, RI
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Black Hills Cardiovascular Research Group
mi
from
Rapid City, SD
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Black Hills Cardiovascular Research Group
mi
from
Rapid City, SD
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Holston Medical Group Clinical Research
mi
from
Kingsport, TN
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Holston Medical Group Clinical Research
mi
from
Kingsport, TN
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Northwest Houston Heart Center
mi
from
Tomball, TX
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Northwest Houston Heart Center
mi
from
Tomball, TX
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
National Clinical Research - Richmond, Inc.
mi
from
Richmond, VA
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
National Clinical Research - Richmond, Inc.
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Northwest Clinical Research Center
mi
from
Bellevue, WA
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Northwest Clinical Research Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Kootenai Heart Clinics
mi
from
Spokane, WA
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Kootenai Heart Clinics
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Clinical Investigation Specialists
mi
from
Kenosha, WI
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Clinical Investigation Specialists
mi
from
Kenosha, WI
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Research and Cardiovascular Corp.
mi
from
Ponce,
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Research and Cardiovascular Corp.
mi
from
Ponce,
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
Grace Research, LLC
mi
from
Bossier City, LA
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
Grace Research, LLC
mi
from
Bossier City, LA
Click here to add this to my saved trials
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated:  2/18/2018
PMG Research of Charleston, LLC
mi
from
Mount Pleasant, SC
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study
Status: Enrolling
Updated: 2/18/2018
PMG Research of Charleston, LLC
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Fayetteville, AR
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Fayetteville, AR
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
San Diego, CA
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Spring Valley, CA
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Spring Valley, CA
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Vista, CA
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Vista, CA
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Golden, CO
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Golden, CO
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Brandon, FL
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Brandon, FL
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Jacksonville, FL
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
mi
from
Longwood, FL
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
mi
from
Longwood, FL
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Ponte Vedra, FL
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Ponte Vedra, FL
Click here to add this to my saved trials
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  2/18/2018
Clinical Research Facility
mi
from
Indianapolis, IN
A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
A Phase 2 Efficacy and Safety Study of LY2484595 Alone and in Combination With Atorvastatin, Simvastatin, and Rosuvastatin in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 2/18/2018
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials